Navigation Links
Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
Date:4/29/2009

are caught early [1].

In 2006, Quest Diagnostics acquired Enterix Inc., manufacturer of the FDA- cleared InSure(R) fecal immunochemical test (FIT) for aiding the detection of colorectal cancer based on stool testing. Quest Diagnostics also made an equity investment in Clinical Genomics, which was formed as a spin off from Enterix's research and development.

[1]American Cancer Society

About Clinical Genomics

Clinical Genomics is a Sydney-based biotechnology company formed in 2006 to exploit the patented and patent-pending gene expression biomarkers of colorectal cancer discovered by its founders and Flinders University in 2001. Clinical Genomics continues to work closely with Flinders University and CSIRO to advance the development of products that will improve the detection and management of this serious disease. Additional information is available at: www.clinicalgenomics.com.


    Contact: (For Clinical Genomics)
    Lawrence LaPointe,
    +61 4 0099 5027,
    larry@clinicalgenomics.com

'/>"/>
SOURCE Clinical Genomics Pty Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
2. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
5. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
6. Clinical Update - Debio 025 in Hepatitis C
7. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
8. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
9. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
10. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
11. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ... based designer, developer and manufacturer of injectable drug delivery ... website at www.unilife.com . The new site includes ... updates to occur on a regular basis. ... stated, "As an emerging global leader for injectable drug ...
(Date:6/18/2013)... , June 18, 2013  Specialty ... significant breakthrough in Parylene coating technologies: SCS ... the benefits of Parylene with antimicrobial properties ... devices and components. (Logo: ... infections (HAIs) increase and continue to pose ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... All pre-specified subset analyses of progression-free survival,in the ... in,relative risk of disease progression for patients receiving,satraplatin. ... as presence or absence of pain. -- The ... - radiologic,progression and pain progression - were each ...
... ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, ... today at the American Society of,Clinical Oncology (ASCO) ... cilengitide in patients with newly diagnosed,glioblastoma – a ... highly selective integrin inhibitor targeting the,tumor and its ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:6/19/2013)... 2013 At a Travel Services Member Conference, ... growth that has occurred over the last year since he ... said, "Travel Services has added vendors, lowered prices of travel ... Membership is up, even in the tough economy, and they've ... members." , Having been in the Travel Business and Timeshare ...
(Date:6/19/2013)... The motor neuron disease Amyotrophic lateral sclerosis (ALS), also ... sequential pattern which can be classified into four distinct ... at the University of Pennsylvania in the Annals ... and spinal cord tissues shows, for the first time, ... starting point in the central nervous system to other ...
(Date:6/19/2013)... from a naturally occurring compound (apocynin), has been ... Parkinson,s Disease symptoms by preventing deficits in motor ... May 28, 2013 edition of Neuroscience ... fellow at the Medical College of Wisconsin (MCW), ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline E. ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
(Date:6/19/2013)... 19, 2013 The US Food and Drug ... ultra cohesive gel breast implant, Mentor Worldwide’s MemoryShape™. , The ... February 2013. The FDA announced the approval of the MemoryShape™ ... primary augmentations in women 22 years old or ... , The FDA’s approval comes after six years of ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2
... between the ages of 40 and 59 could substantially reduce ... the September 9 online issue of the Journal of ... are regularly used in developed countries where the incidence of ... is in place. The value and practicality of such screening ...
... ARBOR, Mich.---Pregnant women who take high levels of daily calcium ... blood, suggesting calcium could play a critical role in reducing ... University of Michigan shows that women who take 1,200 milligrams ... in lead levels. , Women who used lead-glazed ceramics and ...
... still giving them to new moms , , TUESDAY, Sept. ... the majority of East Coast hospitals report giving formula ... medical organizations oppose this practice. , The study, ... of Pediatrics & Adolescent Medicine , surveyed 1,295 ...
... Physician Recruitment Firm Will Grow Through Leadership Development and ... ... Alpharetta, Ga. (Vocus) September 9, 2008 -- ... Jackson president of Alpharetta, Ga.-based http://www.locumtenens.com/new_leader08 [LocumTenens.com]. ...
... that sugar,makes good foods taste better, helps breads rise, ... jams and jellies. But,did you know the same preserving ... heal wounds?, Sugar is one of Mother Nature,s ... sugar an excellent food preservative also bestow,it with its ...
... may be better able to comply with medication regimens ... tables that track what they take and when they ... "medtable" may help to prevent medication-related problems. A report ... Experimental Psychology: Applied, published by the American ...
Cached Medicine News:Health News:Breast cancer screening may lower mortality and disease burden in India 2Health News:Calcium during pregnancy reduces harmful blood lead levels 2Health News:Formula Samples Hinder Breast-Feeding Efforts 2Health News:R. Shane Jackson Named President of LocumTenens.com 2Health News:R. Shane Jackson Named President of LocumTenens.com 3Health News:Sugar's Healing Powers 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 3
... a 60 watt diode continuous wave laser with ... Power Bar technology and 940 nm wavelength make ... for varicose veins and a variety of surgical ... safety features including the LPS, Light guide Protection ...
... is an instrument and LIS independent connectivity ... to work more efficiently than ever. It ... solution that stands between instrument or medical ... important gaps in functionality between the two, ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... the Farnsworth 100 Hue Test comes boxed in ... reduces the potential for test disruption by ... 100 Hue test from Richmond Products includes 93 ... a durable laminated score template for copying, a ...
Medicine Products: